Efforts to develop new drugs that hopefully will never be used

Concerns about terrorist attacks, the prospect of a rogue nation using nuclear weapons and the Fukushima power plant accident in Japan are fostering efforts to develop a new family of drugs that everyone hopes will never be used, according to an article in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, the world's largest scientific society.

Ann M. Thayer, C&EN senior correspondent, explains that the federal government has launched programs to develop medical countermeasures against nuclear threats. Radiation releases can happen under various circumstances, including failure of safety systems at commercial nuclear power plants and . The article describes programs run by the U.S. Food & Administration (FDA), the U.S. Department of Health and Human Services and the National Institutes of Health that support several small companies as they try to develop drugs to treat acute radiation syndrome (ARS).

The article discusses the companies' approaches. Some seek to adapt existing drugs, including treatments for the side effects of radiation therapy for cancer. Thayer notes that because these drugs are already approved by the FDA, stockpiling them would be easier. Others are looking for new compounds that can treat the symptoms of ARS or remove radioactive particles from the body.

More information: "The Drugs That May Never Be Used", cen.acs.org/articles/90/i26/Drugs-Never-Used.html

add to favorites email to friend print save as pdf

Related Stories

Gifts from the Gila monster

Jun 01, 2011

Who would have thought that Gila monster saliva would be the inspiration for a blockbuster new drug for Type 2 diabetes? Or that medicines for chronic pain, heart attacks, high blood pressure and stroke would emerge from ...

Safety testing on Gulf seafood

Jul 20, 2011

Government assurances that seafood from the Gulf of Mexico is safe to eat after the Deepwater Horizon oil spill are the result of a monitoring and testing program that continues more than a year after the April 20, 2010 disaster. ...

Drug companies moving toward green goals

May 31, 2012

Many pharmaceutical companies in a new survey are making progress in embracing the guiding principles of green chemistry, which seek to minimize the use of potentially hazardous substances in producing medications, reduce ...

Nanomedicines promise fewer side effects in treating cancer

Jun 06, 2012

A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments